about
Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infectionCellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important?Hepatitis C virus relies on lipoproteins for its life cycleAlcohol and Viral Hepatitis: Role of Lipid RaftsVitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirinDisease-promoting effects of type I interferons in viral, bacterial, and coinfectionsHepatitis C virus infection.Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trialHepatitis C virus impairs natural killer cell activity via viral serine protease NS3.Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liverActivins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.Heterologous Immunity between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines.Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit.Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C.Inhibitory effect of miR-125b on hepatitis C virus core protein-induced TLR2/MyD88 signaling in THP-1 cellsAssessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure.Accumulation of Intrahepatic TNF-α-Producing NKp44+ NK Cells Correlates With Liver Fibrosis and Viral Load in Chronic HCV InfectionB-Cell Activating Factor Belonging to the Tumor Necrosis Factor Family and Interferon-γ-Inducible Protein-10 in Autoimmune Hepatitis.Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patientsMapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development.The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection.Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study.Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapyISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system.Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy.The role of HCV proteins on treatment outcomes.Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.The impact of chronic hepatitis C infection on cholesterol metabolism in PBMCs is associated with microRNA-146a expression.Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.Interaction effects among IFN-γ+874, IL-2-330, IL-10-1082, IL-10-592 and IL-4-589 polymorphisms on the clinical progression of subjects infected with hepatitis B virus and/or hepatitis C virus: a retrospective nested case-control study.IFNL4 rs368234815 TT>δG Variant is Associated with Liver Damage in Patients with Non-alcoholic Fatty Liver Disease.Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C.Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture.Apoptotic Epitope-Specific CD8+ T Cells and Interferon Signaling Intersect in Chronic Hepatitis C Virus Infection.Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C.MAIT be different-persisting dysfunction after DAA-mediated clearance of chronic hepatitis C virus infection.Hepatitis C may enhance key amplifiers of psoriasis.
P2860
Q24658465-03B0E869-608E-488A-AF1D-521865C62B4CQ26749249-876FCD6B-2543-4B6F-BB1B-C4E9DAEFBCBCQ26766119-2FE3E245-CD16-4D13-BECA-33EBCB16C7ADQ26773213-214BF1D1-2946-477E-85E3-4F55D44A1EFBQ26784321-4E74C960-0CB4-4C8F-A6E9-0025872A127BQ28082841-C65CC8C6-106D-4EDC-BD72-921A88E6AFA7Q30235491-8741A036-643A-4A4C-BD07-A0A661299CE6Q33365130-7A0E38CF-F146-4D90-8ADB-407A4280C852Q33565605-48BE7189-2EE2-4BEC-8006-A1A341DF8270Q33748950-D84DF543-16AA-4638-8F30-82C5540F0438Q35563500-54F8782A-DBCD-421D-976E-29693EC97315Q35889892-EDF9B912-A769-42CD-9626-FE7FF5A041A2Q35958590-E70D6966-8870-430F-85F7-11421CDB10DAQ36675098-D00E4696-DED9-401D-B75C-2BF84E8ACEEEQ36859975-6A86844A-9FE4-4C6E-8171-803AF252BB2AQ36871882-85B2C4F3-53A6-4E28-9CAE-03625EF149A1Q36993610-836CD102-A62F-4960-B872-23038F10B3B7Q37205477-EECB05C3-EABF-4D6D-94D8-4D3A46404330Q37230823-FB2F51E0-9A1D-4BCB-810D-0C70BD3835F9Q37354049-E5B56052-212C-4924-B65E-C6AB7341E23EQ37587194-E35AEBB6-C736-4972-93B4-B46D78A4C46BQ37615221-156C03D0-1410-49EC-993F-9C9DA94EA28DQ37641605-4F9E5F5A-971A-4ACE-9613-AE79304B18C8Q37687572-BA584540-8E14-40C5-A631-19630B7E6285Q38458110-BA293841-8A01-4BFF-A3B2-0624479F9468Q38668968-C10159D6-3E15-467A-AFD2-7E97FB054D54Q38715318-B38E87ED-584C-4844-BAF4-240C4E525CFDQ38844558-5AEFF7BF-A522-4525-8F81-4C9E2D107C46Q38980732-463FE6BB-0264-4CBF-81BA-8C3B8853A995Q39152911-97B5FDD9-D064-4D9E-BDA3-5FEBB7CE59DDQ39432561-1704A968-2229-478F-830D-37958702C090Q40071379-9BBF9BDD-F010-437F-A0C4-885854EA2945Q40121061-A6987D0D-0661-4BD2-8AC7-E5F56510210CQ40279001-D351457E-58AB-482E-B121-7BA39C0DF843Q40320642-22A514CD-06E2-4B51-AD31-65A1A93138A1Q40404561-97EFE9CC-F392-4712-92EF-59D807DD4796Q40522642-3C8715EB-EA47-4F0A-80DD-1FA4FD5053AEQ40523304-A6719662-2397-49E2-9E0F-16AFF4BA8256Q40593130-9677180C-D118-493B-882B-FF0CC8C61CF1Q40672891-DD7EF096-8818-48A6-8CED-5275FF8569E1
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Innate and adaptive immune responses in HCV infections
@ast
Innate and adaptive immune responses in HCV infections
@en
Innate and adaptive immune responses in HCV infections
@nl
type
label
Innate and adaptive immune responses in HCV infections
@ast
Innate and adaptive immune responses in HCV infections
@en
Innate and adaptive immune responses in HCV infections
@nl
prefLabel
Innate and adaptive immune responses in HCV infections
@ast
Innate and adaptive immune responses in HCV infections
@en
Innate and adaptive immune responses in HCV infections
@nl
P3181
P1476
Innate and adaptive immune responses in HCV infections
@en
P2093
Robert Thimme
P304
P3181
P356
10.1016/J.JHEP.2014.06.035
P407
P433
P577
2014-11-01T00:00:00Z